Virtu Financial LLC Acquires 62,881 Shares of Unicycive Therapeutics, Inc. (NASDAQ:UNCY)

Virtu Financial LLC increased its stake in shares of Unicycive Therapeutics, Inc. (NASDAQ:UNCY) by 566.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 73,975 shares of the company’s stock after buying an additional 62,881 shares during the period. Virtu Financial LLC’s holdings in Unicycive Therapeutics were worth $30,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. XTX Topco Ltd bought a new position in shares of Unicycive Therapeutics in the third quarter worth about $29,000. Walleye Capital LLC bought a new position in Unicycive Therapeutics in the 3rd quarter worth approximately $2,040,000. Acuta Capital Partners LLC acquired a new position in Unicycive Therapeutics during the 3rd quarter worth $807,000. Great Point Partners LLC bought a new position in Unicycive Therapeutics in the 3rd quarter valued at $3,491,000. Finally, Bleakley Financial Group LLC acquired a new stake in shares of Unicycive Therapeutics in the 3rd quarter valued at $33,000. Institutional investors own 40.42% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Benchmark reaffirmed a “speculative buy” rating and set a $3.00 price target on shares of Unicycive Therapeutics in a research note on Friday, November 22nd. HC Wainwright restated a “buy” rating and set a $2.50 target price on shares of Unicycive Therapeutics in a research report on Tuesday, November 12th. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $5.13.

Unicycive Therapeutics Trading Down 4.2 %

Shares of UNCY opened at $0.68 on Friday. The stock has a market cap of $70.58 million, a P/E ratio of -0.70 and a beta of 2.36. Unicycive Therapeutics, Inc. has a 1 year low of $0.20 and a 1 year high of $1.82. The stock’s 50-day moving average price is $0.57 and its two-hundred day moving average price is $0.49.

Unicycive Therapeutics Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.